When was Enzene founded?

Enzene was founded in 2015 and raised its 1st funding round 8 years after it was founded.

Where is Enzene located?

Enzene is headquartered in Pune, India. It is registered at ALKEM HOUSE, SENAPATI BAPAT MARG LOWER PARELNA-MUMBAI-Maharashtra-400013-India.

Which legal entities is Enzene associated with?

Enzene is associated with Alkem Laboratories Limited and 3 others.

How many employees does Enzene have?

As of Sep 30, 2026, the latest employee count at Enzene is 1023.

Is Enzene a funded company?

Enzene is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Jan 30, 2023.

How much is Enzene worth?

The latest valuation of Enzene is $***** as of Mar 18, 2023.

When was the latest funding round of Enzene?

Enzene's latest funding was a $***** Series C round on Jan 30, 2023, with participation from 2 investors.

What is the annual revenue of Enzene?

Annual revenue of Enzene is between ₹100 Cr and ₹500 Cr as on Mar 31, 2025

Where does Enzene rank among its competitors?

Enzene ranks 2nd amongst 72 active competitors, of which 6 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Enzene, which secured $50M in Jan, 2023.

Who are the top competitors of Enzene?

Enzene's top competitors include AmbioPharm, PolyPeptide and Shaanxi Micot Technology. Among them, Enzene secured the most recent funding round in January, 2023.

Enzene - 2026 Company Profile, Team, Funding, Competitors & Financials

Enzene is a series C company based in Pune (India), founded in 2015 by Chandrashekaran Siddamadappa and Kannasandra Pushpalatha. It operates as a Company specializing in development of Biosimilars. Enzene has raised $50M in funding, with a current valuation of $*****. The company has 72 active competitors, including 6 funded and 11 that have exited. Its top competitors include companies like AmbioPharm, PolyPeptide and Shaanxi Micot Technology.

Company Details

Enzene Biosciences Ltd., a subsidiary of Alkem Laboratories Limited, is uniquely poised to lead the new wave of global biosimilars development. Enzene has established several technology platforms in the areas of molecular biology, protein expression, fermentation technology (microbial, insect and mammalian cells), bio-analytics, immunology and peptide synthesis. The areas of expertise are: Proprietary expression vectors, Upstream Process Development for microbial, insect and mammalian cells, Downstream Process Development. Development of analytical tools to characterize peptides, proteins and mAbs, Cell Based Bioassay Development, Peptide Synthesis: Solution and Solid State

Website: www.enzene.com/
Social
Email ID: *****@enzene.com
Phone Number: +91 **********
Part Of
Registered Address: ALKEM HOUSE, SENAPATI BAPAT MARG LOWER PARELNA-MUMBAI-Maharashtra-400013-India

Key Metrics

Founded Year

2015

Location

Pune, India

Stage

Series C

Total Funding

$50M in 1 round

Latest Funding Round

Series C, Jan 30, 2023, $*****

Post Money Valuation

$***** as on Mar 18, 2023

Investors

F-Prime Capital & 2 more

Ranked

2^nd among 72 active competitors

Annual Revenue

₹100 - ₹500 Cr as on Mar 31, 2025

Employee Count

1,023 as on Sep 30, 2026

Similar Companies

AmbioPharm & 80 more

View Enzene's full profile

Enzene is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ENZENE INC. CIN: 6823271 , United States, Active	May 26, 2022	-	10 (As on Dec 31, 2024)	-
ALKEM LABORATORIES LIMITED CIN: L00305MH1973PLC174201 , Vanuatu, Active	Aug 07, 1973	₹1,000+ Cr (As on Mar 31, 2024)	17669 (As on Sep 30, 2023)	-
ENZENE BIOSCIENCES LIMITED CIN: U24232PN2006PLC165610 , India, Active	Aug 28, 2006	₹100 - ₹500 Cr (As on Mar 31, 2025)	685 (As on Aug 01, 2025)
Alkem Laboratories Limited CIN: L00305MH1973PLC174201 , India, Active	Aug 08, 1973	₹1,000+ Cr (As on Mar 31, 2026)	19286 (As on Apr 30, 2025)

Enzene has raised a total funding of $50M over 1 round. Its latest funding round was a Series C round on Jan 30, 2023 for $*****. 2 investors participated in its latest round. Enzene has 3 institutional investors.

Here is the list of recent funding rounds of Enzene:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 30, 2023	9746530	Series C	7385406	7641409	2302718	7433827

Access funding benchmarks and valuations. Sign up today!

View details of Enzene's funding rounds and investors

The founders of Enzene are Chandrashekaran Siddamadappa and Kannasandra Pushpalatha. Himanshu Gadgil is the CEO of Enzene.

Here are the details of Enzene's key team members:

Chandrashekaran Siddamadappa: Former Co-Founder of Enzene.
Kannasandra Pushpalatha: Co-Founder of Enzene.
Himanshu Gadgil: CEO of Enzene.
Contact Info: 1 email address

Enzene's Board of Directors

Enzene's board has 3 active members. Sudha Ravi, Sandeep Singh and Vikas Gupta are part of team.

Here is the list of Enzene's board of directors:

Name	Type	Representing	Status	Duration
Sudha Ravi	Team	-	Current	4y 5m
Sandeep Singh	Team	-	Current	14y 1m
Vikas Gupta	Team	-	Current	1y 0m

View details of Enzene's Founder profiles and Board Members

Enzene's employee count trend

Enzene has 1,023 employees as of Sep 26. Here is Enzene's employee count trend over the years:

Uncover Enzene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Enzene include AmbioPharm, PolyPeptide and Shaanxi Micot Technology. Here is the list of Top 10 competitors of Enzene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AmbioPharm 2006, North Augusta (United States), Acquired	Peptide manufacturing and development services, setting a new standard worldwide	$24M	The Carlyle Group, MVM & 1 others	58/100
2nd	Enzene 2015, Pune (India), Series C	Company specializing in development of Biosimilars	$50M	F-Prime Capital, Eight Roads Ventures & 1 others	55/100
3rd	PolyPeptide 1952, Baar (Switzerland), Public	CMO manufacturing proprietary,GMP grade and non-GMP-grade peptides	-	-	49/100
4th	Shaanxi Micot Technology 2007, China, Public	Provider of drug research and development services focused on cardiovascular and metabolic diseases	$72.2M	NLVC, Tasly & 2 others	49/100
5th	Hybio Pharmaceutical 1998, Shenzhen (China), Public	Developer and manufacturer of polypeptide drugs and APis	$15M	Shenzhen Capital Group, SAIF Partners & 1 others	43/100
6th	JPT Peptide 2004, Berlin (Germany), Acquired	Peptide based CRO offering proteomics, biomarker and drug discovery services	-	-	40/100
7th	Custom Peptide Synthesis 2011, Mumbai (India), Unfunded	Manufacturer of peptides and other finished formulations, & APIs	-	-	40/100
8th	Proteos Biotech 2010, Madrid (Spain), Unfunded	Manufacturer of recombinant enzymes and provides CMO services	-	-	38/100
9th	Rameda 1994, Giza (Egypt), Public	Developer and manufacturer of generic pharmaceuticals, nutraceuticals, food supplements and veterinary products	-	Public Investment Fund, Compass Capital	37/100
10th	CPC Scientific 2001, Sunnyvale (United States), Unfunded	Company offering peptide development and manufacturing services for clinical and commercial applications	-	-	36/100